Kathy Petoumenos1, Jun Yong Choi2, Jennifer Hoy3, Sasisopin Kiertiburanakul4, Oon Tek Ng5,6, Mark Boyd1,7, Reena Rajasuriar8,9, Matthew Law1. 1. The Kirby Institute, UNSW Sydney, Sydney, Australia. 2. Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea. 3. Department of Infectious Diseases, The Alfred Hospital and Monash University, Melbourne, Australia. 4. Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 5. Department of Infectious Disease and Communicable Disease Centre, Tan Tock Seng Hospital, Singapore. 6. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. 7. Discipline of Medicine, University of Adelaide, Adelaide, Australia. 8. Centre of Excellence for Research in AIDS (CERiA), University of Malaya, Kuala Lumpur, Malaysia. 9. Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Abstract
BACKGROUND: In the era of effective antiretroviral treatment (ART) CD4:CD8 ratio is proposed as a potential marker for HIV-positive (HIV+) patients at increased risk for non-AIDS comorbidities. The current study aims to compare CD4:CD8 ratio between Asian and Caucasian HIV+ patients. METHODS: HIV+ patients from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD) meeting specific criteria were included. In these analyses Asian and Caucasian status were defined by cohort. Factors associated with a low CD4:CD8 ratio (cutoff <0.2) prior to ART commencement, and with achieving a normal CD4:CD8 ratio (>1) at 12 and 24 months post ART commencement were assessed using logistic regression. RESULTS: There were 591 patients from AHOD and 2,620 patients from TAHOD who met the inclusion criteria. TAHOD patients had a significantly (P<0.001) lower odds of having a baseline (prior to ART initiation) CD4:CD8 ratio greater than 0.2. After 12 months of ART, AHOD patients were more than twice as likely to achieve a normal CD4:CD8 ratio compared to TAHOD patients (15% versus 6%). However, after adjustment for confounding factors there was no significant difference between cohorts in the odds of achieving a CD4:CD8 ratio >1 (P=0.475). CONCLUSIONS: We found a significantly lower CD4:CD8 ratio prior to commencing ART in TAHOD compared to AHOD even after adjusting for confounders. However, after adjustment, there was no significant difference between the cohorts in odds of achieving normal ratio. Baseline CD4+ and CD8+ counts seem to be the main driver for this difference between these two populations.
BACKGROUND: In the era of effective antiretroviral treatment (ART) CD4:CD8 ratio is proposed as a potential marker for HIV-positive (HIV+) patients at increased risk for non-AIDS comorbidities. The current study aims to compare CD4:CD8 ratio between Asian and Caucasian HIV+ patients. METHODS: HIV+ patients from the Australian HIV Observational Database (AHOD) and the TREAT Asia HIV Observational Database (TAHOD) meeting specific criteria were included. In these analyses Asian and Caucasian status were defined by cohort. Factors associated with a low CD4:CD8 ratio (cutoff <0.2) prior to ART commencement, and with achieving a normal CD4:CD8 ratio (>1) at 12 and 24 months post ART commencement were assessed using logistic regression. RESULTS: There were 591 patients from AHOD and 2,620 patients from TAHOD who met the inclusion criteria. TAHOD patients had a significantly (P<0.001) lower odds of having a baseline (prior to ART initiation) CD4:CD8 ratio greater than 0.2. After 12 months of ART, AHOD patients were more than twice as likely to achieve a normal CD4:CD8 ratio compared to TAHOD patients (15% versus 6%). However, after adjustment for confounding factors there was no significant difference between cohorts in the odds of achieving a CD4:CD8 ratio >1 (P=0.475). CONCLUSIONS: We found a significantly lower CD4:CD8 ratio prior to commencing ART in TAHOD compared to AHOD even after adjusting for confounders. However, after adjustment, there was no significant difference between the cohorts in odds of achieving normal ratio. Baseline CD4+ and CD8+ counts seem to be the main driver for this difference between these two populations.
Authors: Sine Reker Hadrup; Jan Strindhall; Tania Køllgaard; Tina Seremet; Boo Johansson; Graham Pawelec; Per thor Straten; Anders Wikby Journal: J Immunol Date: 2006-02-15 Impact factor: 5.422
Authors: Amit C Achhra; Jialun Zhou; Jun Yong Choi; Jennifer Hoy; Fujie Zhang; David J Templeton; Tuti Merati; Ian Woolley; Kathy Petoumenos; Janaki Amin Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2011-04-20
Authors: F van Leth; F W N M Wit; P Reiss; J K M E Schattenkerk; M E van der Ende; M M E Schneider; J W Mulder; P H J Frissen; F de Wolf; J M A Lange Journal: HIV Med Date: 2004-03 Impact factor: 3.180
Authors: Victor Leung; Jennifer Gillis; Janet Raboud; Curtis Cooper; Robert S Hogg; Mona R Loutfy; Nima Machouf; Julio S G Montaner; Sean B Rourke; Chris Tsoukas; Marina B Klein Journal: PLoS One Date: 2013-10-30 Impact factor: 3.240
Authors: Sergio Serrano-Villar; María Jesús Pérez-Elías; Fernando Dronda; José Luis Casado; Ana Moreno; Ana Royuela; José Antonio Pérez-Molina; Talia Sainz; Enrique Navas; José Manuel Hermida; Carmen Quereda; Santiago Moreno Journal: PLoS One Date: 2014-01-30 Impact factor: 3.240
Authors: Sergio Serrano-Villar; Talia Sainz; Sulggi A Lee; Peter W Hunt; Elizabeth Sinclair; Barbara L Shacklett; April L Ferre; Timothy L Hayes; Ma Somsouk; Priscilla Y Hsue; Mark L Van Natta; Curtis L Meinert; Michael M Lederman; Hiroyu Hatano; Vivek Jain; Yong Huang; Frederick M Hecht; Jeffrey N Martin; Joseph M McCune; Santiago Moreno; Steven G Deeks Journal: PLoS Pathog Date: 2014-05-15 Impact factor: 6.823
Authors: Carl J Fichtenbaum; Heather J Ribaudo; Jorge Leon-Cruz; Edgar T Overton; Markella V Zanni; Carlos D Malvestutto; Judith A Aberg; Emma M Kileel; Kathleen V Fitch; Marije Van Schalkwyk; Nagalingeswaran Kumarasamy; Esteban Martinez; Breno Riegel Santos; Yvetot Joseph; Janet Lo; Sue Siminski; Kathleen Melbourne; Craig A Sponseller; Patrice Desvigne-Nickens; Gerald S Bloomfield; Judith S Currier; Udo Hoffmann; Pamela S Douglas; Steven K Grinspoon Journal: J Infect Dis Date: 2020-07-09 Impact factor: 7.759
Authors: Christina L Kong; Nicole K Kelly; Miel Sundararajan; S R Rathinam; John A Gonzales; Radhika Thundikandy; Rajesh Vedhanayaki; Anuradha Kanakath; Bala Murugan; Thuy Doan; Debra Goldstein; Hassan A Al-Dhibi; Nisha R Acharya Journal: Ocul Immunol Inflamm Date: 2020-08-11 Impact factor: 3.070